BTLA antibodies

TW202633923APending Publication Date: 2026-08-16OXFORD UNIVERSITY INNOVATION LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
TW115116672
Authority / Receiving Office
TW · TW
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-06-11
Filing Date
2021-06-10
Publication Date
2026-08-16

Smart Images

  • Figure TWG2TA001073573_001
    Figure TWG2TA001073573_001
  • Figure TWG2TA001073573_002
    Figure TWG2TA001073573_002
  • Figure TWG2TA001073573_003
    Figure TWG2TA001073573_003
Patent Text Reader

Abstract

This invention relates generally to antibodies that bind to human B and T lymphocyte attenuator (BTLA) and uses thereof. More specifically, the invention relates to agonistic antibodies that bind human BTLA and modulate its activity, and their use in treating inflammatory, autoimmune and proliferative diseases and disorders. Suitably, the antibodies also possess an Fc modification that enhances signalling through FcɣR2B.
Need to check novelty before this filing date? Find Prior Art